NeoMetrix Dx, Inc., based in the San Francisco Bay Area and founded by a group of well-respected neonatologists and experienced business executives, is developing the world’s first automated in-vitro medical diagnostic device to measure newborns’ risk of neurological damage. Our patented technology provides clinicians with personalized information to accurately diagnose neonatal risk of hyperbilirubinemia in an efficient and cost-effective way.

NeoMetrix Dx, Inc. was founded to satisfy an unmet neonatal clinical need affecting over 70% of the 3.8 million babies born in the US annually and is applicable to tens of millions of newborns worldwide. We are uniquely positioned to rapidly dominate this billion-dollar market, while significantly reducing the cost of healthcare and protecting the health of tens of millions of babies born each year.